Hypertrophic Cardiomyopathy: For Patients, Their Families and Interested Physicians: Second Edition

Hypertrophic Cardiomyopathy: For Patients, Their Families and Interested Physicians: Second Edition

Volumn , Issue , 2007, Pages 1-113

  Maron, Barry J ^a   Salberg, Lisa ^b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b Hypertrophic Cardiomyopathy Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891302775     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470750896     Document Type: Book

References (39)

1. Arad M, Maron BJ, Gorham JM, Johnson WH Jr., Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-72.
2. Elliot PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome MT, McKenna WJ. Historical trends in reported survival rates in patients with hypertrophy cardiomyopathy. Heart 2006;92:785-91.
3. Fibroozi S, Elliott PM, Sharma S, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, hemodynamic, and exercise outcomes. Eur Heart J 2002;23:1617-1624.
4. Hauser RG, Maron BJ. Lessons from the failure and recall of an implantable cardioverter defibrillator. Circulation 2005;112:2040-2042.
5. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2004;109:452-456.
6. Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 2003;92:1183-1186.
7. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. J Am Med Assoc 2002;287:1308-1320.
8. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064-1075.
9. Maron BJ. Hypertrophic cardiomyopathy: An important global disease (Editorial). Am J Med 2004;116:63-65.
10. Maron BJ. Surgery for hypertrophic obstructive cardiomyopathy: Alive and quite well. Circulation 2005;111:2016-2018.
11. Maron BJ, Zipes DP. 36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes with Cardiovascular Abnormalities. J Am Coll Cardiol 2005;45:1312-1375.
12. Maron BJ, Thompson PD, Puffer JC, McGrew CA, Strong WB, Douglas PS, Clark LT, Mitten MJ, Crawford MH, Atkins DL, Driscoll DJ, Epstein AE. Cardiovascular preparticipation screening of competitive athletes. Circulation 1996;94:850-856.
13. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. J Am Med Assoc 1999;281:650-655.
14. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind cross-over study (M-PATHY). Circulation 1999;99:2927-2933.
15. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral based patient population. Circulation 2000;102:858-864.
16. Maron BJ, Shen W-K, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NAM III, Spirito P, Casey SA, Stanton MS, Betocchi S. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-373.
17. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced ages. J Am Coll Cardiol 2003;42:882-888.
18. Maron BJ, Estes NAM III, Maron MS, Almquist AK, Link MS, Udelson J. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003;107:2872-2875.
19. Maron BJ, Barry JA, Poole RS. Pilots, hypertrophic cardiomyopathy and issues of aviation and public safety. Am J Cardiol 2004;93:441-444.
20. Maron BJ, Chaitman B, Ackerman MJ, Bayés de Luna A, Corrado D, Crosson JE, Deal BJ, Driscoll DJ, Estes NAM III, Araújo CG, Liang DH, Mitten MJ, Myerburg RJ, Pelliccia A, Thompson PD, Towbin JA, Van Camp SP. American Heart Association Scientific Statement: Recommendations for Physical Activity and Recreational Sports Participation for Young Patients with Genetic Cardiovascular Diseases. Circulation 2004;109:2807-2816.
21. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, Nishimura RA. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:2044-2053.
22. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, ten Cate FJ, Wigle ED. Pocket Guidelines on Hypertrophic Cardiomyopathy. Joint Task Force on Clinical Expert Consensus Documents of the American College of Cardiology Foundation and the European Society of Cardiology Committee for Practice Guidelines, 2004, pp. 1-16.
23. Maron MS, Zenovich AG, Casey SA, Link MS, Udelson JE, Aeppli DM, Maron BJ. Significance and relation between magnitude of left ventricular hypertrophy and heart failure systems in hypertrophic cardiomyopathy. Am J Cardiol 2005;95:1329-1333.
24. Matthews T, Dickinson J. Considerations for delivery in pregnancies complicated by maternal hypertrophic obstructive cardiomyopathy. Aust N Z J Obstet Gynaecol 2005;45:526-528.
25. McCully RB, Nishimura RA, Tajik AJ, Schaff HZ, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-471.
26. Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004;350:1320-1327.
27. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, Allison TG, Tajik AJ. Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind cross-over study. J Am Coll Cardiol 1997;29:435-441.
28. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-2524.
29. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-476.
30. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38:1994-2000.
31. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:855-861.
32. Seggewiss H, Gleichman U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-258.
33. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251-1258.
34. Spirito P, Rapezzi C, Bellone P, et al. Infective endocarditis in hypertrophic cardiomyopathy. Prevalence, incidence and indications for antibiotic prophylaxis. Circulation 1999;99:2132-2137.
35. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-1785.
36. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc 2005;80:739-744.
37. van Langen IM, Birnie E, Schuurman E, Tan HL, Hofman N, Bonsel GJ, Wilde AA. Preferences of cardiologists and clinical geneticists for the future organization of genetic care in hypertrophic cardiomyopathy: Asurvey. Clin Genet 2005;68:360-368.
38. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, Siu S, Ralph-Edwards A, Rakowski H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033-2041.
39. Yang Z, McMahon CJ, Smith LR, Bersola J, Adesina AM, Breinholt JP, Kearney DL, Dreyer WJ, Denfield SW, Price JF, Grenier M, Kertesz NJ, Clunie SK, Fernbach SD, Southern JF, Berger S, Towbin JA, Bowles KR, Bowles NE. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005;112:1612-1617.